Home » Clinical Trials » Leukemia » NCT06078306
NCT06078306

Clinical Trial for the Safety and Efficacy of Induction Chemotherapy With Azacitidine+Venetoclax (VA) and Bridging CD19CD22 CAR-T Therapy in Adult Patients With Newly Diagnosed High-Risk and Ph-negative (Ph-) B-ALL

Study Summary

Clinical trial for the safety and efficacy of induction chemotherapy with VA regime and bridging CD19CD22 CAR-T therapy in adult patients with newly diagnosed high-risk and Ph- B-ALL

Want to learn more about this trial?

Request More Info

Interventions

Azacitidine InjectionDRUG
Azacitidine Injection 75mg/square meter/day, day1-7, subcutaneous injection
VenetoclaxDRUG
Venetoclax 100mg day 1, 200mg day 2, 400mg d3-d21, oral
CD19CD22 CAR-TDRUG
After induction chemotherapy with Azacitidine+Venetoclax, each subject receives CD19CD22 CAR-T cells by intravenous infusion

Study Locations

FacilityCityStateCountry
Xiaowen TangSuzhouJiangsuChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026